AIBotics, Inc. filings document its SEC reporting status as an OTC operating company and include Form 12b-25 notifications tied to delayed annual and quarterly reports. Those notices identify the registrant, the reporting periods for the Form 10-K and Form 10-Q, and the company’s reliance on SEC late-filing procedures when reports could not be filed within the prescribed period.
The filing themes center on reporting compliance, registrant information and the timing of periodic disclosures. For this issuer, the documents provide regulatory context around annual and quarterly reporting obligations while its public-company record identifies AIBotics with AI-enabled robotics and automation activities.
Aibotics, Inc. reports minimal revenue of $2,183 for the year ended December 31, 2025, against a net loss of $2,215,751. Operating expenses were largely general and administrative at $1,846,856, plus $371,078 of interest and extinguishment losses.
Cash was $255,940 with a working capital deficit of $4,564,798 and an accumulated deficit of $13,025,007, leading management and auditors to highlight substantial doubt about the company’s ability to continue as a going concern. Current liabilities of $4,834,905 include significant convertible debt and related-party obligations.
The company shifted strategy toward AI-powered consumer devices through the Philon Labs asset acquisition and continues historic psychedelic-related activities. Common shares outstanding rose to 486,895,359 as of December 31, 2025, with further issuance to 567,695,492 shares by April 15, 2026, reflecting heavy equity-based financing and liability settlements.
Aibotics Inc. submitted a Form 12b-25 notifying the SEC that its annual report on Form 10-K for the period ended December 31, 2025 could not be filed on time because the company required additional time to complete its audit procedures. The notification was signed on March 31, 2026.
Aibotics, Inc. (AIBT) reported another loss-making quarter for Q3 2025 with almost no revenue and a heavy debt load. The company generated no revenue in the quarter and only $2,183 for the first nine months of 2025, while recording a net loss of $529,921 for Q3 and $1,607,467 for the nine-month period, slightly higher than a year ago.
At September 30, 2025, Aibotics held $230,470 in cash against current liabilities of $4,902,572, resulting in a working capital deficit of $4,661,176 and a stockholders’ deficit of $3,885,629. Management states these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
To meet obligations, Aibotics relied on issuing and converting large amounts of common stock, expanding outstanding shares from 39,990,903 at December 31, 2024 to 318,890,559 at September 30, 2025, with further issuances after quarter-end. Several convertible notes remain in default, and the company continues to depend on new debt and equity financing.
Aibotics Inc. (AIBT) filed a Form 12b-25 (NT 10-Q) for the quarter ended September 30, 2025, notifying a late quarterly report. The company cites the need for additional time for auditor review. Under Rule 12b-25(b), it expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date. The notice lists Jonathan Leinwand as the contact and is signed by CEO and CFO Ben Kaplan.